STOCK TITAN

OptimizeRx to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
OptimizeRx Corp. (OPRX) announces participation in investor conferences to engage with investors. The Company will be present at Barclays 26th Annual Global Healthcare Conference and 36th Annual ROTH Conference for discussions and one-on-one meetings.
Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), the leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 

  • Barclays 26th Annual Global Healthcare Conference, Miami Beach, March 13th, 2024
  • 36th Annual ROTH Conference, Dana Point, March 17th – March 19th, 2024

Management will be participating in a fireside chat and will be holding one-on-one meetings with investors. To request a meeting or for more details about the conferences please reach out to your institutional contacts.

Conference Details: 

Barclays 26th Annual Global Healthcare Conference
Date: Wednesday, March 13th
Format:Fireside Chat & 1x1 Meetings
Location:The Loews Miami Beach Hotel

   

36th Annual ROTH Conference
Date: March 17th – March 19th
Format:Fireside Chat & 1x1 Meetings
Location:The Ritz Carlton Laguna Niguel
  

About OptimizeRx 
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 2 million U.S. healthcare providers and millions of their patients through an intelligent technology platform embedded within a proprietary digital point-of-care network, as well as mass digital communication channels, OptimizeRx helps life sciences organizations engage and support their customers. 

For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.  

Important Cautions Regarding Forward Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans, and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.  

OptimizeRx Contact  
Andy D’Silva, SVP Corporate Finance 
adsilva@optimizerx.com 

Media Relations Contact  
Dilma Bennett, Media Relations Manager 
dbennett@optimizerx.com 

Investor Relations Contact 
Ashley Robinson 
LifeSci Advisors, LLC 
arr@lifesciadvisors.com 


FAQ

When will OptimizeRx Corp. (OPRX) participate in the Barclays 26th Annual Global Healthcare Conference?

OptimizeRx Corp. (OPRX) will participate in the Barclays 26th Annual Global Healthcare Conference on March 13th, 2024.

Which investor conference will OptimizeRx Corp. (OPRX) attend for one-on-one meetings?

OptimizeRx Corp. (OPRX) will be present at the 36th Annual ROTH Conference for one-on-one meetings from March 17th to March 19th, 2024.

What type of meetings will OptimizeRx Corp. (OPRX) have at the investor conferences?

OptimizeRx Corp. (OPRX) will participate in fireside chats and hold one-on-one meetings with investors at the upcoming conferences.

OptimizeRx Corporation

NASDAQ:OPRX

OPRX Rankings

OPRX Latest News

OPRX Stock Data

193.11M
15.06M
11.86%
72.33%
3.61%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
United States of America
WALTHAM

About OPRX

optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.